N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Phase 2 N=39 Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma With Sarcomatoid Features
Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants
Phase 2 N=5 Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Response Rate — 0 percentage of participants
Phase 2 N=34 Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 5.5 Months
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
Phase 2 N=55 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients
Phase 2 N=25 Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 12 Weeks
Phase 2 N=106 A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants
Phase 2 N=39 Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Best Overall Response Rate — 5 percentage of participants
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Phase 2 N=10 Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Phase 3 N=435 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 2 N=20 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Phase 2 N=52 Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Kidney Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants
Phase 2 N=94 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants
Phase 2 N=39 A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 5.1 percentage of participants
Phase 2 N=72 Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma · Neoplasm Metastases
Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…
Phase 3 N=416 RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Metastatic Renal Cell Carcinoma
Primary: Progressive Free Survival (PFS) in Patients Who Receive RAD001 Plus Best Supportive Care(BSC) Versus Patients Who Receive Matching Placebo Plus BSC — 4.90; 1.87 Months
N/A N=618 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
Phase 2 N=92 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants
N/A N=19 Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Kidney Cancer · Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Initial Objective Response- First Participation — 5; 1; 7; 4 Participants
Phase 2 N=45 Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Efficacy of Pembrolizumab and Cabozantinib Based on Objective Response Rate — 65.8; 0 % of patients
Phase 2 N=74 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Carcinoma, Renal Cell
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
Phase 2 N=108 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Phase 2 N=30 Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Renal Cell Carcinoma
Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs